Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Hauenstein · SciRah

Researcher profile · Semantic Scholar

S. Hauenstein

Share profile

S. Hauenstein — researcher profile on SciRah

h-index: 18
Works: 61
Citations: 2,124

Most-cited papers

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
N. V. Casteele, A. Gils, Sharat Singh, L. Ohrmund +3 more
2013American Journal of Gastroenterology369 citations
Semantic Scholar
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
Niels Vande Casteele, R. Khanna, B. Levesque, L. Stitt +11 more
2014Gut292 citations Open access
Semantic Scholar
Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum.
Shui-Long Wang, L. Ohrmund, S. Hauenstein, J. Salbato +5 more
2012JIM - Journal of Immunological Methods220 citations Open access
Semantic Scholar
Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy.
A. Yarur, Maddie J. Kubiliun, Frank Czul, D. Sussman +9 more
2015Clinical Gastroenterology and Hepatology167 citations Open access
Semantic Scholar
Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy.
F. Baert, D. Drobne, A. Gils, Niels Vande Casteele +5 more
2014Clinical Gastroenterology and Hepatology130 citations Open access
Semantic Scholar
Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis
A. Yarur, A. Jain, S. Hauenstein, M. Quintero +5 more
2016Inflammatory Bowel Diseases107 citations Open access
Semantic Scholar
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease
B. Levesque, G. Greenberg, G. Zou, W. Sandborn +10 more
2014Alimentary Pharmacology and Therapeutics98 citations Open access
Semantic Scholar
Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial
F. Baert, V. Kondragunta, S. Lockton, Niels Vande Casteele +6 more
2015Gut97 citations
Semantic Scholar
Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay.
Shui-Long Wang, S. Hauenstein, L. Ohrmund, R. Shringarpure +7 more
2013Journal of Pharmaceutical and Biomedical Analysis93 citations Open access
Semantic Scholar
Shape-selective RNA recognition by cysteinyl-tRNA synthetase
S. Hauenstein, Chun-mei Zhang, Ya-Ming Hou, J. Perona
2004Nature Structural &Molecular Biology93 citations
Semantic Scholar
Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission.
K. Papamichael, Niels Vande Casteele, A. Gils, S. Tops +7 more
2015Clinical Gastroenterology and Hepatology85 citations
Semantic Scholar
Antibodies to Infliximab Are Associated with Lower Infliximab Levels and Increased Likelihood of Surgery in Pediatric IBD
N. Zitomersky, B. Atkinson, Kerri Fournier, P. Mitchell +8 more
2015Inflammatory Bowel Diseases48 citations Open access
Semantic Scholar
Redundant Synthesis of Cysteinyl-tRNACys in Methanosarcina mazei*
S. Hauenstein, J. Perona
2008Journal of Biological Chemistry45 citations Open access
Semantic Scholar
565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD)
B. Feagan, Sharat Singh, S. Lockton, S. Hauenstein +6 more
201239 citations Open access
Semantic Scholar
The Homotetrameric Phosphoseryl-tRNA Synthetase from Methanosarcina mazei Exhibits Half-of-the-sites Activity*
S. Hauenstein, Ya-Ming Hou, J. Perona
2008Journal of Biological Chemistry38 citations Open access
Semantic Scholar
Kinetic quality control of anticodon recognition by a eukaryotic aminoacyl-tRNA synthetase.
Cui-Ping Liu, H. Gamper, Svetlana Shtivelband, S. Hauenstein +2 more
2007Journal of Molecular Biology34 citations Open access
Semantic Scholar
490 Prevalence of Antibodies to Adalimumab (ATA) and Correlation Between Ata and Low Serum Drug Concentration on CRP and Clinical Symptoms in a Prospective Sample of IBD Patients
F. Velayos, S. Sheibani, S. Lockton, S. Hauenstein +3 more
201333 citations
Semantic Scholar
Tu1147 Serum Adalimumab Levels and Antibodies Correlate With Endoscopic Intestinal Inflammation and Inflammatory Markers in Patients With Inflammatory Bowel Disease
A. Yarur, A. Deshpande, D. Sussman, S. Hauenstein +4 more
201327 citations
Semantic Scholar
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia
D. Shelton, Prasanthi Bhagavatula, N. Sepúlveda, L. Beppu +4 more
2022PLoS ONE17 citations Open access
Semantic Scholar
563 Antibodies to Infliximab Can Either Be Persistent or Transient: A Retrospective Case-Control Study in IBD Patients Treated With Infliximab Maintenance Therapy
N. V. Casteele, L. Cuypers, Sharat Singh, L. Ohrmund +5 more
201212 citations Open access
Semantic Scholar
Sa1247 Antibodies to Adalimumab Predict Inflammation in Crohn's Patients on Maintenance Adalimumab Therapy
F. Baert, S. Lockton, S. Hauenstein, Sharat Singh +2 more
20148 citations
Semantic Scholar
Tu1135 Serum Adalimumab and Immunogenicity in IBD Patients After 80mg Biweekly Maintenance Therapy
O. Ben-Bassat, S. Hauenstein, A. Iacono, S. Irwin +2 more
20138 citations
Semantic Scholar
Early Trough Levels and Antibodies Predict Safety and Success of Restarting Infliximab After Long Drug Holiday
F. Baert, D. Drobne, V. Ballet, A. Gils +6 more
20118 citations Open access
Semantic Scholar
Tu1155 Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-up and Impact of Infliximab Trough Levels and Antibodies to Infliximab
D. Sorrentino, S. Hauenstein, M. Marino, S. Lockton +3 more
20136 citations Open access
Semantic Scholar
Su1928 Comparison of Homogeneous Mobility Shift Assay and Solid Phase ELISA for the Measurement of Drug and Anti-Drug Antibody (ADA) Levels in Serum From Patients Treated With Anti-TNF Biologics
S. Hauenstein, L. Ohrmund, J. Salbato, Rukmini G. Reddy +5 more
20126 citations
Semantic Scholar
P253 Transient versus sustained antibodies to infliximab: Possibility to overcome low titer antibody responses by dose optimisation
N. Van de Casteele, L. Cuypers, Sharat Singh, S. Hauenstein +5 more
20126 citations Open access
Semantic Scholar
Homogenous Mobility Shift Assay (HMSA) Overcomes the Limitations of ELISA and ECLIA Assays for Monitoring Infliximab (IFX), Adalimumab (ADA), and Associated Anti-drug Antibodies in Serum: 1817
Laia Egea-Pujol, Rukmini G. Reddy, Shruti Patel, R. Christie +4 more
20135 citations
Semantic Scholar
Tu1148 Mechanisms of Loss of Response to Adalimumab in Crohn's Disease
D. Wolf, S. Hauenstein, S. Lockton, Sharat Singh
20134 citations
Semantic Scholar
Su1192 A Multi-Center Observational Study in Community Gastroenterology Practices Evaluating the Clinical Usage of Testing for Serum Levels of Infliximab and Antibodies to Infliximab
D. Wolf, S. Lockton, S. Hauenstein, S. Carroll +2 more
20134 citations Open access
Semantic Scholar
Sa1249 Infliximab and Antibody to Infliximab Concentrations in 7,613 Patients Shows Indication for Testing, Association With Loss of Response and Provides New Insights Into Binding Characteristics of Anti-Drug Antibodies
N. V. Casteele, Katherine A. Drake, S. Hauenstein, B. Levesque +2 more
20143 citations
Semantic Scholar
788 Higher 6-Thioguanine Nucleotide Concentrations Are Associated With Higher Trough Levels of Infliximab in Patients on Combination Therapy
A. Yarur, Maddie J. Kubiliun, Katherine A. Drake, S. Hauenstein +6 more
20143 citations
Semantic Scholar
Tu1164 Comparison of Early Measurement of Infliximab and Antibodies-to-Infliximab Serum Levels With Standard Trough Analysis
A. Eser, C. Primas, S. Hauenstein, S. Lockton +2 more
20133 citations
Semantic Scholar
Validation of a Homogenous Mobility Shift Assay (HSMA) for the Measurement of Golimumab (GLM) and Antibodies to Golimumab (ATG) in Inflammatory Bowel Disease (IBD) Patient Serum: 1794
J. Salbato, J. Parnell, Rukmini G. Reddy, R. Christie +4 more
20133 citations
Semantic Scholar
DOP063 Biomarker panel for prediction of mucosal healing in patients with Crohn's disease under infliximab therapy
M. de Bruyn, T. Bessissow, T. Billiet, I. Cleynen +11 more
20142 citations
Semantic Scholar
Su1394 Prediction of Sustained Remission After Discontinuation of Infliximab in Patients With Crohn's Disease
K. Papamichail, N. V. Casteele, S. Hauenstein, F. Princen +6 more
20142 citations Open access
Semantic Scholar
Correlation of Intestinal Tissue Anti-TNF Drug Levels with Endoscopic Disease Activity in Patients with Inflammatory Bowel Disease: The ATLAS Study: 1826
A. Yarur, S. Hauenstein, D. Sussman, J. Barkin +5 more
20132 citations
Semantic Scholar
Su1172 Characterization of Neutralizing Anti-Drug Antibody Response in Patients With Loss of Response to Anti-TNF Therapy
S. Hauenstein, J. Salbato, S. Lockton, Sharat Singh
20132 citations
Semantic Scholar
Evaluation of a Novel Homogeneous Mobility Shift Assay for the Measurement of Human Antibodies-to-Infliximab and Infliximab Levels in Patient Serum: 1254
Shui-Long Wang, L. Ohrmund, S. Hauenstein, J. Salbato +5 more
20112 citations
Semantic Scholar
Serology panel for prediction relapse after discontinuation of infliximab in patients with Crohn's disease achieving clinical remission
K. Papamichael, K. Claes, M. de Bruyn, S. Hauenstein +6 more
20151 citations Open access
Semantic Scholar
Serum Certolizumab Pegol Levels and Antibodies to Certolizumab Pegol Are Associated With C-Reactive Protein Levels in Patients With Crohn’s Disease: 1770
A. Yarur, S. Hauenstein, Frank Czul, S. Lockton +5 more
20141 citations
Semantic Scholar
Su1292 Biomarker Panel for Prediction of Mucosal Healing in Patients With Crohn's Disease Under Infliximab Therapy
M. de Bruyn, T. Bessissow, T. Billiet, I. Cleynen +11 more
20141 citations
Semantic Scholar
Comparison of Techniques for Monitoring Infliximab and Antibodies to Infliximab in Crohnʼs Disease Patients with Infliximab Treatment Failure: 1546
C. Steenholdt, J. Brynskov, O. Thomsen, L. Munck +11 more
20121 citations
Semantic Scholar
Evolution of cysteinyl -tRNA(Cys) formation within the three domains of life
S. Hauenstein
20071 citations
Semantic Scholar
B-160 Streamlining Syphilis Serology Through an Automated Multiplex Syphilis Total and RPR Panel
Xu Han, Wei-Ming Zheng, Shu-Xia Zhou, Mariana Portella +4 more
2026Clinical Chemistry0 citations
Semantic Scholar
An overview of HIV and HCV viral load monitoring.
S. Hauenstein
2016MLO: medical laboratory observer0 citations
Semantic Scholar
Tu1344 Serology Panel for Prediction of Relapse After Discontinuation of Infliximab in Patients With Crohn's Disease Achieving Clinical Remission
K. Papamichael, K. Claes, M. de Bruyn, F. Princen +6 more
20150 citations
Semantic Scholar
Sa1269 Improved Homogeneous Mobility Shift Assay (HMSA) for the Detection of Neutralizing Antibodies (NAB) in IBD Patients Treated With Infliximab or Adalimumab
Kelly D. Hester, Xin-Jun Liu, J. Salbato, S. Lockton +2 more
20140 citations Open access
Semantic Scholar
Tu1728 Signaling Pathway Proteins Are Associated With Inflammation and Disease Location in IBD: Implications for Mucosal Healing and Malignancy Risk
A. Yarur, Katherine A. Drake, A. Jain, J. Barkin +6 more
20140 citations
Semantic Scholar
Sa1254 Anti-Tumor Necrosis Factor Levels Are Not Associated With Intestinal Extent of Mucosal Inflammation in Patients With Inflammatory Bowel Diseases
A. Yarur, Katherine A. Drake, Maddie J. Kubiliun, R. Dauer +6 more
20140 citations Open access
Semantic Scholar
Sa1200 Presence and Concentration of OmpC As a Risk Factor for Developing Antibodies to Infliximab (ATI): Implications for Selecting Patients With Inflammatory Bowel Disease (IBD) for Combination Therapy
S. Lockton, Dhara D Shah, F. Princen, S. Hauenstein +4 more
20140 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Sharat Singh×41
Invite
Sharat Singh — researcher profile on SciRah
S. Lockton×25
Invite
S. Lockton — researcher profile on SciRah
S. Vermeire×15
Invite
S. Vermeire — researcher profile on SciRah
P. Rutgeerts×12
Invite
P. Rutgeerts — researcher profile on SciRah

×10

Invite

A. Gils — researcher profile on SciRah

Invite

L. Ohrmund — researcher profile on SciRah

Invite

J. Salbato — researcher profile on SciRah

Invite

A. Yarur — researcher profile on SciRah

Invite

J. Barkin — researcher profile on SciRah

Invite

M. Abreu — researcher profile on SciRah

Invite

M. Quintero — researcher profile on SciRah

Katherine A. Drake×7

Invite

Katherine A. Drake — researcher profile on SciRah